A mechanistic approach of 3-Monochloropropane-1, 2-diol (3-MCPD) toxicity: Emphasis on flow cytometry

Publish Year: 1398
نوع سند: مقاله کنفرانسی
زبان: English
View: 693

نسخه کامل این Paper ارائه نشده است و در دسترس نمی باشد

  • Certificate
  • من نویسنده این مقاله هستم

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

TOXICOLOGY15_044

تاریخ نمایه سازی: 15 بهمن 1398

Abstract:

Introduction: 3-Monochloropropane-1,2-diol (3-MCPD) is a recognized contaminant that has been caused in a varied range of food materials. The formation of 3-MCPD occurred in foods containing fat and salt which are exposed to high temperatures in manufacturing process. It supposed that the kidney and liver are the main and sensitive endpoint target organ for 3-MCPD. Unfortunately, due to limited facts about possible 3-MCPD production and mechanistic toxicity, we design an investigation to determine the role of oxidative stress based on increased of ROS formation following 3-MCPD exposure. Material and Methods: We tested a range of 3-MCPD concentration (0.01-10 mM) in HEK-293 cell line on isolated mitochondria and cells (0.01, 0.2, 0.5,1 and 2 mM). The cytotoxicity assay in HEK-293 cell line, the isolated cell and mitochondria were performed for evaluation of multiple oxidative stress markers. Results: Our pilot data revealed that the 3-MCPD cytotoxicity is not concentration dependent manner and only the highest cytotoxicity in HEK-293 was observed in lowest concentration of 3-MCPD (10μM). Also, the highest rise in ROS level, MMP collapse and increase in apoptotic cells were observed in isolated kidney or liver cells, without any change in oxidative stress markers in isolated mitochondria. Discussion: It suggested that 3-MCPD can interact with mitochondrial electron transfer which is correlated to induction of ROS production and MDA level, decrease in GSH, and failure in mitochondrial membrane potential which start programmed cell death signaling.

Authors

Firoozeh Nazari

Food and Drug Administration-Iran University of Medical Sciences, Tehran, Iran

Parvaneh Naserzadeh

Nanomedicine and Tissue Engineering Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran- Department of Pharmacology and Toxicology, Faculty of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Rana Dizaji

Zanjan Pharmaceutical Biotechnology Research Center, School of Pharmacy, Zanjan University of Medical Sciences, Zanjan, Iran

Hamidreza Kheiri Manjili

Zanjan Pharmaceutical Biotechnology Research Center, School of Pharmacy, Zanjan University of Medical Sciences, Zanjan, Iran

Hadis Bahrami

Zanjan Pharmaceutical Biotechnology Research Center, School of Pharmacy, Zanjan University of Medical Sciences, Zanjan, Iran

Mina Soleimani

Food and Drug Administration-Iran University of Medical Sciences, Tehran, Iran